Sort   by:  
 Page size 
TranscriptomicsExpression data from normal and MDS erythroids cell cutlures ex vivo
CD34 positive cells of bone marrow samples from normal and MDS samples were cultured ex vivo into erythroid conditions. We used microarrays to detail the gene expression programm of erythroid cells between normal and pathological (MDS) samples Mononuclear cells from bone marrow samples were selected...
ORGANISM(S): Homo sapiens 
2012-02-14 | E-GEOD-34268 | biostudies-arrayexpress
TranscriptomicsThe TCR activation acts as a tumor suppressor mechanism in T-ALL
Developmental checkpoints in stem/progenitor cells are critical to the determination, commitment and differentiation into distinct lineages. Cancer cells often retain expression of lineage-specific checkpoint proteins, but their potential impact in cancer remains elusive. T lymphocytes mature in the...
ORGANISM(S): Homo sapiens 
2016-08-20 | E-GEOD-65496 | biostudies-arrayexpress
TranscriptomicsTranscription profiling of human blood from acute promyelocytic leukemia patients using different differentiating agents
Differentiating agents have been proposed to overcome the impaired cellular differentiation in acute myeloid leukemia (AML). However, only the combinations of all-trans retinoic acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute promyelocytic leukemia (also c...
ORGANISM(S): Homo sapiens 
2010-03-23 | E-TABM-925 | biostudies-arrayexpress
UnknownEffect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.

Background

Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a recombinant human IL-1 receptor antagonist, could improve outcomes in patients in hospital with mild-...
S-EPMC7825875 | biostudies-literature
UnknownSarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial.

Background

Patients with COVID-19 pneumonia can have increased inflammation and elevated cytokines, including interleukin (IL)-6, which might be deleterious. Thus, sarilumab, a high-affinity anti-IL-6 receptor antibody, might improve the outcome of patients with moderate-to-severe COVID-19 p...
S-EPMC8598187 | biostudies-literature
Sort   by:  
 Page size